Endothelial dysfunction: potential clinical implications.
Tousoulis
D
D
Hippokration Hospital, Athens University Medical School, Greece. drtousoulis@hotmail.com
Koutsogiannis
M
M
Papageorgiou
N
N
Siasos
G
G
Antoniades
C
C
Tsiamis
E
E
Stefanadis
C
C
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control; D001708:Biopterins / Q000031:analogs & derivatives / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000502:physiology; D005492:Folic Acid / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007333:Insulin Resistance; D009569:Nitric Oxide / Q000096:biosynthesis; D012307:Risk Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001708:Biopterins; D009569:Nitric Oxide; D005492:Folic Acid; C003402:sapropterin